AZ suspends two NSCLC combo trials

AstraZeneca plc (LSE:AZN; NYSE:AZN) temporarily suspended the Phase Ib TATTON trial and Phase III CAURAL trial of AZD9291 in combination with durvalumab ( MEDI4736) to treat non-small cell lung cancer (NSCLC). Spokesperson Abigail Bozarth said the trials were halted due to reports of interstitial lung disease (ILD)-like events.

Bozarth said that in the TATTON trial, ILD-like events were reported in 6 of 23 previously treated patients and 5 of 10 treatment-naive patients that received AZD9291 plus durvalumab. No deaths as a result of ILD have been reported. ...